Fresolimumab

Idiopathic Pulmonary Fibrosis (IPF) Clinical Landscape Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Pharmaceutical, Health, Clinical trials, Medical devices, Idiopathic pulmonary fibrosis, Lung disorders, Boehringer Ingelheim, Pulmonary fibrosis, IPF, Health, Orphan drugs, Organ systems, Monoclonal antibodies, Pneumonia, Fresolimumab

The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The majority of industry-sponsored drugs in active clinical development for IPF are in Phase I.
  • Roche leads the industry sponsors with the highest overall number of clinical trials for IPF, closely followed by Boehringer Ingelheim.

US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight to 2026: Insight on FDA Approved 57 Cancer Antibodies Available in the US Market

Retrieved on: 
Friday, April 9, 2021
Life sciences, Medical specialties, Immunology, Clinical medicine, Biotechnology, Antibody, Glycoproteins, Biosimilar, Cancer, Monoclonal antibody therapy, Fresolimumab

DUBLIN, April 9, 2021 /PRNewswire/ -- The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 9, 2021 /PRNewswire/ -- The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e.
  • In the US, technology advancement is also considered a democratizing force for boosting the market paradigm for cancer-antibody drug market.
  • US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
    US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
    Insight On Clinical Trials by Company, Indication, Patient Segment & Phase
    US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026
    9.

US Cancer Biosimilar Market Opportunity Insight: Upwards of US$ 10 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 6, 2021
Pharmaceutical, Health, Oncology, Life sciences, Medical specialties, Immunology, Clinical medicine, Biotechnology, Antibody, Glycoproteins, Biosimilar, Cancer, Fresolimumab, Monoclonal antibody therapy

The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e.
  • In the US, technology advancement is also considered a democratizing force for boosting the market paradigm for cancer-antibody drug market.
  • US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
    US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
    Insight On Clinical Trials by Company, Indication, Patient Segment & Phase
    US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026
    9.

US Cancer Antibodies Market Oncology Antibody Clinical Trials Forecast Report 2026

Retrieved on: 
Friday, March 12, 2021
Medical specialties, Immunology, Clinical medicine, Medicine, Monoclonal antibodies, Biotechnology, Antibody, Glycoproteins, Antineoplastic drugs, Cancer, Antibody-drug conjugate, Fresolimumab

NEW DELHI, March 12, 2021 /PRNewswire/ -- "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 12, 2021 /PRNewswire/ -- "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:
    US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
    US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
    Insight On Clinical Trials by Company, Indication, Patient Segment & Phase
    US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026
    The clinical research report, US cancer antibody therapy market brings together the past, current and the future aspects of the market.
  • In the US, cancer antibody therapy market is considered to be one of the most exciting cancer therapies in the entire industry.
  • The US cancer antibody market in the past few years have also overachieved the hurdle of anticipating the therapy market as a pioneering leader and this could be analyzed by observing the total sales of the drugs.
  • The US cancer antibody drug market has already stretched the healthcare opportunities related with the therapy.

US Cancer Antibodies Market Oncology Antibody Clinical Trials Forecast Report 2026

Retrieved on: 
Friday, March 12, 2021
Medical specialties, Immunology, Clinical medicine, Medicine, Monoclonal antibodies, Biotechnology, Antibody, Glycoproteins, Antineoplastic drugs, Cancer, Antibody-drug conjugate, Fresolimumab

NEW DELHI, March 12, 2021 /PRNewswire/ -- "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 12, 2021 /PRNewswire/ -- "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:
    US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
    US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
    Insight On Clinical Trials by Company, Indication, Patient Segment & Phase
    US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026
    The clinical research report, US cancer antibody therapy market brings together the past, current and the future aspects of the market.
  • In the US, cancer antibody therapy market is considered to be one of the most exciting cancer therapies in the entire industry.
  • The US cancer antibody market in the past few years have also overachieved the hurdle of anticipating the therapy market as a pioneering leader and this could be analyzed by observing the total sales of the drugs.
  • The US cancer antibody drug market has already stretched the healthcare opportunities related with the therapy.

Global Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 20, 2021
Health, General Health, Medical specialties, Health sciences, Kidney diseases, Clinical research, Health, Glomerulosclerosis, Drug discovery, Pharmaceutical industry, Design of experiments, Clinical trial, Focal segmental glomerulosclerosis, Fresolimumab

The "Global Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Focal Segmental Glomerulosclerosis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Focal Segmental Glomerulosclerosis market.
  • It covers emerging therapies for Focal Segmental Glomerulosclerosis in active clinical development stages including early and late stage clinical trials.
  • The report provides Focal Segmental Glomerulosclerosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2

Retrieved on: 
Tuesday, December 22, 2020
Monoclonal antibodies, Muscular dystrophy, Idiopathic pulmonary fibrosis, Drugs, Pamrevlumab, Clinical medicine, Health, Duchenne muscular dystrophy, Simtuzumab, Fresolimumab

Subjects who complete the 52-week study may be eligible for rollover into a separate study offering open-label, extension treatment with pamrevlumab.

Key Points: 
  • Subjects who complete the 52-week study may be eligible for rollover into a separate study offering open-label, extension treatment with pamrevlumab.
  • The Phase 3 clinical development program for pamrevlumab for IPF consists of two studies, ZEPHYRUS and ZEPHYRUS-2.
  • Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of locally advanced unresectable pancreatic cancer (LAPC), and in Phase 2 clinical development for the treatment of Duchenne muscular dystrophy (DMD).The U.S. Food and Drug Administrationhas granted Orphan Drug Designation (ODD) to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD.
  • Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).

Global Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Highlights 2020: Clinical Trial Stages, Drug Mechanism Classes, Short-term Launch Highlights - ResearchAndMarkets.com

Retrieved on: 
Friday, September 11, 2020
Pharmaceutical, Health, Clinical trials, Medical specialties, Health, Kidney diseases, Clinical research, Clinical medicine, Drug discovery, Pharmaceutical industry, Glomerulosclerosis, Design of experiments, Focal segmental glomerulosclerosis, Clinical trial, Fresolimumab

The "Global Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The report Focal Segmental Glomerulosclerosis Pipeline Highlights - 2020, provides the most up-to-date information on key pipeline products in the global Focal Segmental Glomerulosclerosis market.
  • It covers emerging therapies for Focal Segmental Glomerulosclerosis in active clinical development stages including early and late-stage clinical trials.
  • The report provides Focal Segmental Glomerulosclerosis pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Idiopathic Pulmonary Fibrosis (IPF) Market Spotlight 2019-2027: Roche's Esbriet and Boehringer Ingelheim's Ofev are the only approved drugs for IPF - ResearchAndMarkets.com

Retrieved on: 
Monday, November 4, 2019
Health, General Health, Breakthrough therapy, Idiopathic pulmonary fibrosis, RTT, Health, Boehringer Ingelheim, Chemical compounds, Organic compounds, Nintedanib, Pirfenidone, IPF, Boehringer, Fresolimumab

The "Market Spotlight: Idiopathic Pulmonary Fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Idiopathic Pulmonary Fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.
  • Roche's Esbriet and Boehringer Ingelheim's Ofev are the only approved drugs for IPF.
  • Industry-sponsored drugs in active clinical development for IPF are spread evenly across Phase I and Phase II, with two drugs in Phase III.
  • Boehringer Ingelheim leads industry sponsors with the highest overall number of clinical trials for IPF, followed by Roche.

Global Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Highlights, 2019 - Analysis on Clinical Trial Stages, Drug Mechanism Classes, Short-term Launch Highlights, and Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, June 14, 2019
Health, Clinical trials, Pharmaceutical, Medical specialties, Health, Kidney diseases, Medicine, Glomerulosclerosis, Clinical research, Design of experiments, Drug discovery, Focal segmental glomerulosclerosis, Clinical trial, Fresolimumab

The "Global Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Highlights, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Highlights, 2019" report has been added to ResearchAndMarkets.com's offering.
  • This report provides most up-to-date information on key pipeline products in the global Focal Segmental Glomerulosclerosis market.
  • It covers emerging therapies for Focal Segmental Glomerulosclerosis in active clinical development stages including early and late stage clinical trials.
  • The report provides Focal Segmental Glomerulosclerosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.